Business Wire

New ISACA Certification Helps Students and Career Changers Build IT Knowledge and Hands-On Skills to Thrive in IT Jobs

16.3.2021 18:12:00 EET | Business Wire | Press release

Share

Those seeking a strong foundation in IT knowledge and hands-on experience to set themselves apart as they seek technology jobs can now earn the new Information Technology Certified Associate (ITCA) certification from global IT professional association and learning organization ISACA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005796/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

As the need for skilled technology professionals continues to grow, the IT field presents numerous promising career paths for young professionals, recent graduates and career-changers. ISACA’s new Information Technology Certified Associate (ITCA) credential – which includes certificates in Computing Fundamentals, Networks and Infrastructure Fundamentals, Cybersecurity Fundamentals, Data Science Fundamentals and Software Development Fundamentals – prepares aspiring professionals for entry into an array of IT fields. (Graphic: Business Wire)

A dynamic addition to ISACA’s globally recognized credentials, ITCA offers students, recent graduates, those new to the IT profession or professionals seeking a career change with a flexible, hybrid format comprised of traditional knowledge-based learning and performance-based learning through live labs in a virtual environment. The certification can be achieved at one’s own pace by completing all the following modular certificates that focus on different domain areas in IT:

  • Computing Fundamentals
  • Networks and Infrastructure Fundamentals
  • Cybersecurity Fundamentals
  • Software Development Fundamentals
  • Data Science Fundamentals

“A key part of ISACA’s commitment to providing tools for lifelong learning is supporting professionals at every stage of their career journey, including in that critical period at the very beginning—whether they are new graduates or professionals seeking to make a career change to IT,” says David Samuelson, ISACA CEO. “We are proud to be able to serve this new generation of IT professionals and thought leaders, including those transitioning their careers due to the pandemic, by helping them differentiate and elevate themselves as they enter the job market and start their careers.”

With ITCA, young professionals, students or recent graduates with degrees in IT or computer science, and those seeking a job change can prepare themselves for in-demand jobs like computer systems administrator, technical support specialist, database administrator, systems engineer, applications developer, front-end web developer, and quality assurance analyst. The certification can also serve more experienced audit, security or governance professionals looking to enhance their understanding of foundational IT concepts.

“Working within the IT industry presents so many amazing opportunities for recent graduates, young professionals and career-changers,” says Daisy Jardine-Viner, recruitment specialist, NDK Infosec. “It’s a constantly evolving and in-demand hiring environment that offers the chance to work at the forefront of technology.”

The ITCA program offers study guides, self-paced training courses, performance-based labs, and exams for each certificate, available at discounted rates to ISACA members. Once all five exams are completed, the candidate can apply to become ITCA certified.

For more information about ITCA, visit www.isaca.org/credentialing/itca. Learn more about ISACA’s other credentials at www.isaca.org/credentialing.

About ISACA

For more than 50 years, ISACA® (www.isaca.org) has been equipping individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enables enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release

Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release

Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior

European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye